Building on the success of 2013, the second ESMO Symposium on Signalling Pathways in Cancer will focus on the PI3K/AKT/mTOR pathway. The programme has been designed provide oncology professionals with the latest scientific developments behind molecular pathways in cancer and a personalised approach to cancer treatment.

This unique oncology meeting brings together academic, clinical and industry researchers, practicing and young oncologists – all stakeholders working in different tumour settings but sharing common underlining mechanisms and signalling pathways.